Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-11-02
2003-03-04
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S352000
Reexamination Certificate
active
06528527
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to a method of treatment of bronchial and respiratory disorders with a therapeutic combination of a PDE4 inhibitor and a leukotriene antagonist. In particular, the present invention is directed to a method of treatment of bronchial and respiratory disorders with a therapeutic combination of ROFLUMILAST and SINGULAIR.
Cyclic nucleotide phosphodiesterase (PDE) inhibitors, particularly inhibitors of type IV (PDE4), are useful in the treatment of bronchial and respiratory disorders such as asthma and chronic obstuction pulminary disease (COPD). N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (ROFLUMILAST, BYK Gulden Lomberg Chemische Fabrik GmbH, Konstanz, Germany) is a PDE4 inhibitor described in U.S. Pat. No. 5,712,298.
Leukotriene antagonists, by a route different from PDE4 inhibitors, are also useful in the treatment of bronchial and respiratory disorders such as asthma and COPD. Montelukast, [R-(E)]-1-[[[1-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)-phenyl]propyl]thio]methyl]cyclopropaneacetic acid, (SINGULAIR, Merck & Co., Inc, Rahway, N.J.) is a leukotriene antagonist described in U.S. Pat. No. 5,565,473. Other leukotriene antagonists are described in U.S. Pat. Nos. 4,649,157, 4,845,083, 5,028,615, and 5,244,899.
It would be desirable to provide a method that can take advantage of the different therapeutic pathways of a PDE4 inhibitor and of a leukotriene antagonist to more efficaciously treat asthma and COPD.
SUMMARY OF THE INVENTION
Bronchial and respiratory disorders are treated by the separate, sequential, or simultaneous administration of i) an amount of N-(3,5-dichloropyrid-4-yl)-cyclopropylmethoxy-4-difluoromethoxybenzamide, the pyridyl N-oxide thereof, or a pharmaceutically acceptable salt of either compound; and ii) an amount of a leukotriene antagonist, wherein the sum of the first and second amounts is a therapeutically effective amount.
REFERENCES:
patent: 5565473 (1996-10-01), Belley et al.
patent: 5712298 (1998-01-01), Amschler
K.F. Chung, Allergol. Int., (1998), vol. 47(4): pp. 237-246.
H.J. Dyke, et al., Expert Opinion on Investigational Drugs, (1999), vol. 8/9:pp. 1301-1325.
Henley III Raymond
Merck & Co. , Inc.
Rose David L.
LandOfFree
Method of treatment with a combination of a PDE4 inhibitor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment with a combination of a PDE4 inhibitor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment with a combination of a PDE4 inhibitor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3041080